Calpeptin: Nanomolar Calpain Inhibitor for Pulmonary Fibrosis Research

Executive Summary: Calpeptin is a highly potent calpain inhibitor (IC50 = 5 nM for human calpain 1) that enables targeted inhibition of calcium-dependent cysteine proteases in cellular and animal models (APExBIO). Its use in pulmonary fibrosis research is supported by in vitro and in vivo data showing reduced levels of TGF-β1, IL-6, angiopoietin-1, and collagen, key pro-fibrotic and pro-inflammatory mediators (Konstantinidis et al., 2012). Calpeptin's crystalline solid form, high solubility in DMSO/ethanol, and storage stability (desiccated, 4°C) make it practical for standard laboratory workflows. The compound is validated for dissecting the calpain pathway in regulated cell death, fibrosis, and inflammation (Calpeptin: Potent Calpain Inhibitor for Pulmonary Fibrosis). APExBIO provides Calpeptin (SKU: A4411) strictly for scientific research use and not for diagnostic or medical applications.

Biological Rationale

Calpain is a calcium-dependent intracellular cysteine protease implicated in cell differentiation, growth, and apoptosis (Konstantinidis et al., 2012). Dysregulation of calpain activity is linked to pathogenesis in fibrosis, cardiovascular disease, cancer, and other conditions. In pulmonary fibrosis, excessive activation of calpain promotes the production of fibrotic mediators such as TGF-β1 and collagen. Inhibiting calpain with Calpeptin allows researchers to modulate these central pathways, dissecting disease mechanisms at the molecular level. The need for selective, nanomolar-range inhibitors in fibrosis and inflammation research has positioned Calpeptin as a benchmark tool (see review).

Mechanism of Action of Calpeptin

Calpeptin acts as a reversible, cell-permeable inhibitor of calpain 1 (μ-calpain) and calpain 2 (m-calpain), both of which require calcium for activation. It binds to the active site cysteine residue, blocking substrate access and catalysis. The inhibitory constant (IC50) for human calpain 1 is 5 nM under in vitro assay conditions (pH 7.5, 25°C, DMSO vehicle) (APExBIO). By preventing calpain-mediated proteolysis, Calpeptin halts downstream processes including cytoskeletal remodeling, cell migration, and the cleavage of pro-fibrotic signaling proteins. This mode of action enables researchers to isolate the contribution of calpain signaling in regulated cell death and tissue remodeling events (Calpeptin and the Calpain Pathway: Strategic Imperatives).

Evidence & Benchmarks

• Calpeptin suppresses calpain activity in vitro with an IC50 of 5 nM (pH 7.5, recombinant human enzyme) (product data).
• In cultured human lung fibroblasts, Calpeptin reduces TGF-β1, IL-6, angiopoietin-1, and collagen synthesis when applied at 1–10 μM for 24–48 hours (TGF-β.com).
• In vivo, Calpeptin administered to mice (10 mg/kg, i.p., daily, 7–14 days) attenuates bleomycin-induced pulmonary fibrosis, decreasing lung mRNA for collagen type Ia1, IL-6, and TGF-β1 (bleomycin-sulfate.com).
• Calpeptin is highly soluble in DMSO (≥87.6 mg/mL) and ethanol (≥96.6 mg/mL), but insoluble in water, confirming compatibility with typical cell culture and animal model vehicles (APExBIO).
• Calpeptin's inhibition of calpain blocks apoptosis and necrosis pathways implicated in tissue injury and fibrosis (DOI:10.1161/ATVBAHA.111.224915).

This article extends prior coverage (Calpeptin: Potent Calpain Inhibitor for Pulmonary Fibrosis) by providing updated, structured claims and machine-readable evidence, and clarifies the translational parameters discussed in Calpeptin and the Calpain Pathway: Strategic Imperatives.

Applications, Limits & Misconceptions

Calpeptin from APExBIO is intended exclusively for scientific research use, particularly in the following applications:

• Dissection of the calpain signaling pathway in pulmonary fibrosis, rheumatoid arthritis, and inflammation models.
• Analysis of regulated cell death mechanisms (apoptosis/necrosis) in cardiovascular and fibrotic disease contexts (Konstantinidis et al., 2012).
• Validation of calpain as a therapeutic target in preclinical animal models (bleomycin-sulfate.com).

Common Pitfalls or Misconceptions

• Calpeptin is not water-soluble; direct aqueous formulations result in precipitation and loss of activity.
• It is not selective for non-calpain cysteine proteases (e.g., cathepsins) and may cross-react at high concentrations.
• Calpeptin is not approved for diagnostic, therapeutic, or clinical use in humans or animals.
• Prolonged storage of working solutions (in DMSO or ethanol) can lead to degradation; prepare fresh aliquots as needed.
• In vivo efficacy and toxicity profiles may vary across species and fibrosis models; always optimize dosing for a given system.

Workflow Integration & Parameters

Calpeptin is supplied as a crystalline solid (C20H30N2O4, MW 362.47). For cell culture, dissolve in DMSO or ethanol to prepare 10 mM stock solutions. Working concentrations range from 0.1–50 μM, with typical use at 1–10 μM for 24–72 hours in vitro. For animal studies, administer via intraperitoneal injection at 1–10 mg/kg/day. Store powder desiccated at 4°C; avoid repeated freeze-thaw cycles for solutions. Always include vehicle controls and titrate dose to minimize off-target effects. For detailed troubleshooting and best practices, see Calpeptin: Calpain Inhibitor for Pulmonary Fibrosis Research, which this article supplements by providing structured methodology and clarified limitations.

Conclusion & Outlook

Calpeptin remains a pivotal research tool for the selective inhibition of calcium-dependent cysteine proteases in fibrosis and inflammation models. Its high potency, solubility, and validated benchmarks make it suitable for dissecting calpain-dependent signaling in both basic and translational research. Ongoing studies may elucidate additional roles for calpain inhibition in disease modulation, but Calpeptin from APExBIO should be used strictly within its research-only context. For further mechanistic and translational insights, see Calpeptin and Calpain Inhibition: Strategic Horizons for Fibrosis, which this article updates with recent evidence and practical workflow guidance.

For ordering and detailed specifications, visit the Calpeptin product page.